UC Davis Comprehensive Cancer Center | Strategic Alliance Partners

UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 100,000 adults and children every year and access to more than 200 active clinical trials at any given time. Its innovative research program engages more than 240 scientists at UC Davis who work collaboratively to advance discovery of new tools to diagnose and treat cancer. Patients have access to leading-edge care, including immunotherapy and other targeted treatments. Its Office of Community Outreach and Engagement addresses disparities in cancer outcomes across diverse populations, and the cancer center provides comprehensive education and workforce development programs for the next generation of clinicians and scientists. For more information, visit cancer.ucdavis.edu.

Latest from UC Davis Comprehensive Cancer Center


Gender, Racial, and Socioeconomic Status Disparities Linked With Incidence of Metastatic Bone Disease

January 26, 2022

R. Lor Randall, MD, speaks to the findings from a report that said multiple sex-related, racial/ethnic, and socioeconomic status disparities are associated with an increased incidence of metastatic bone disease originating from cancers in the prostate, renal, colon, lung, and breast.

Compressive Osseointegrated Endoprostheses Provide Long-Term Benefit in Bone Sarcoma

November 18, 2021

R. Lor Randall, MD, FACS, the 10-year results of a retrospective analysis, potential strategies to mitigate early failures in recipients of compressive osseointegrative endoprosthetic devices, and the need for communication between medical oncologists and orthopedic surgeons to ensure patients on chemotherapy receive optimal care.

Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC

October 07, 2021

David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.

Gandara Named Chief Medical Officer of International Society for Liquid Biopsy

August 04, 2021

David R. Gandara, MD has been appointed chief medical officer of the International Society for liquid biopsy, an international non-profit organization dedicated to advancing the field of liquid biopsy in cancer diagnosis and management.

MRD Offers a Potential Predictive Strategy to Further Personalize Treatment in NSCLC

July 29, 2021

Although the predictive utility of minimal residual disease has yet to be fully realized in non–small cell lung cancer, it has the potential to guide treatment decisions in earlier lines of treatment, including the adjuvant setting.